INTRODUCTION
Atherosclerosis and vascular calcification (VC) are common complications of chronic kidney disease (CKD) and significant risk factors for cardiovascular disease and mortality. 1, 2 VC is currently recognized as an actively regulated process dependent on the balance between its inducers and inhibitors. 3 Several studies have shown that arterial calcification resembles bone formation. In a uremic environment, vascular groups. All enrolled patients were nonsmoking Caucasians (22 men; mean age, 60 ±3.0 years, and 20 women, mean age, 56 ±1.5 years) and had pharmacologically well-controlled hypertension.
Information concerning medical history, medications, cardiovascular complications, and results of routine laboratory measurements was obtained from chart reviews. The causes of renal failure were chronic glomerulonephritis in 15 cases, diabetic nephropathy in 8, polycystic kidney disease in 4, hypertensive nephropathy in 5, tubulointerstitial nephritis in 3, and unknown in 7 patients.
The randomization cards were prepared on the assumption that twice the number of patients would be treated with both vitamins, K 2 and D, than with vitamin D alone (active vs control group). Patients were randomized to each group by computer. Twenty-nine patients in the K+D group received an oral dose of 90 μg of vitamin K 2 (menaquinone-7, MK-7) plus 10 μg of cholecalciferol per day for 270 ±12 days; 13 in group D received 10 μg of cholecalciferol alone (FIGURE 1). The tablets containing vitamin K 2 +D or vitamin D were identical in size and appearance (both types of tablets were prepared by NattoPharma, Høvik, Norway). Patients from both groups were treated with statins because of hyperlipidemia. Four patients from group K+D and two from group D received calcium carbonate as a phosphate binder with doses unmodified throughout the study.
Anthropometric measurements were taken and fasting blood samples for biochemical, blood count, and coagulation tests were obtained at the time of randomization and at the end of treatment. Routine serum parameters, including creatinine, calcium, phosphate, parathyroid hormone, glucose, albumin, total protein, cholesterol, triglycerides, and high-density lipoprotein cholesterol levels were measured with routine laboratory methods, low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. The eGFR was calculated with a 4-variable Modification of Diet in Renal Disease (MDRD) equation. Serum and plasma samples were prepared after standard centrifugation and frozen at -80°C until measurements.
Circulating total MGP was measured using a sandwich enzyme immunoassay by an enzyme--linked immunosorbent assay (ELISA; USCN Life Science Inc, www.uscnk.com), while plasma desphosphorylated-uncarboxylated MGP (dp-ucMGP) was assessed using the inaKtif MGP iSYS kit (Immunodiagnostic Systems; www.idsplc), which is a dual-antibody test based on the previously described sandwich ELISA (developed by VitaK, Maastricht University, The Netherlands), total serum OC by ELISA (Immunodiagnostic Systems; www.idsplc), serum osteoprotegerin (OPG) by ELISA (Immunodiagnostic Systems; www.idsplc), serum fetuin A by ELISA (Epitope Diagnostics,Inc., www.epitopediagnostics. com), serum 25-hydroxyvitamin D [25(OH)D] by a radioimmunoassay (IBL International; www. IBL-International.com), serum high-sensitive the vessel wall. MGP needs to undergo posttranslational gammaglutamyl carboxylation to achieve full biologic activity. The carboxylation process is completely dependent on the availability of vitamin K, which is a cofactor of this process.
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Natural vitamin K consists of phylloquinone (vitamin K 1 ) and the menaquinones MK-4 through MK-10, all vitamin K 2 . Both vitamin K 1 and K 2 catalyze the gammaglutamyl carboxylation of all vitamin K-dependent proteins. However, vitamin K 1 predominantly accumulates in the liver and is the most important substance for the activation of coagulation factors, while vitamin K 2 has a more widespread tissue distribution and is thus more specifically involved in the carboxylation of MGP. 8 Consequently, it exerts a major role in the calcification process. In cases of vitamin K deficiency, MGP is not activated and undercarboxylated MGP predominantly accumulates in the areas of VC, and is associated with both intimal and medial calcification. 9 Observational studies have shown that high dietary vitamin K 2 intake is associated with a reduced risk of coronary vascular disease and VC. 10, 11 The second vitamin exerting multiple functions including a role in the calcification process is vitamin D.
12 Recent data have demonstrated a high prevalence of suboptimal levels of vitamins K and D in patients with CKD stages 3 to 5.
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The aim of this study was to assess the effect of supplementation of vitamin K 2 (menaquinone, MK-7) in combination with a low dose of cholecalciferol compared with cholecalciferol alone on the progression of atherosclerosis and coronary artery calcification (CAC) and on circulating levels of calcification regulators in nondialyzed CKD patients.
PATIENTS AND METHODS
This prospective, randomized, and double-blind study was conducted between 2009 and 2012. Multislice computed tomography (CT) scanning of the thorax to assess the coronary calcification score (CACS) and ultrasonography of the common carotid artery with the measurement of intima-media thickness (CCA-IMT) were performed on the same day in 75 consecutive nondialyzed patients with CKD stages 3-5 from a single nephrology outpatient clinic who fulfilled the inclusion and exclusion criteria.
The inclusion criteria were as follows: age from 18 to 70 years old, a history of stable estimated glomerular filtration rate (eGFR <60 ml/min/1.73 m 2 ) over at least 6 months, not requiring dialysis. The exclusion criteria were as follows: a history of major cardiovascular complications (myocardial infarction, clinically significant arrhythmia including atrial fibrillation, congestive heart failure, stroke, peripheral vascular disease), history of thrombosis or coagulation disorders, treatment with oral anticoagulants, steroid and other hormonal therapies, and treatment with vitamin D or its analogs. Forty-two screened patients showed CACS values of 10 Agatston units (AU) or higher, and they were randomized to the study Ultrasonographic studies were performed with a "VIVID 7 PRO" apparatus (GE) using a 5-14-MHz linear high-resolution probe. Each patient was examined in the supine position in a semi-dark room by the same expert radiologist who was blinded to the purpose of the study, the results of CACS, and the allocation to the treatment group. CCA-IMT was defined as a low--level echo grey band that does not project into the arterial lumen and was measured at the diastolic phase as a distance between the leading edge of the first and second echogenic line. CCA-IMT was measured on the longitudinal views of the far wall of the distal segment of the common carotid artery, by means of a semiautomatic border-detection program 0.5, 1, and 2 cm below and above the bifurcation in a plaque-free arterial segment, and the mean value from all measurements from both carotids was used for statistical analysis. 13, 14 The analysis was performed off-line on a workstation equipped with a dedicated software (EchoPac PC, GE Medical System).
Statistical analysis
The results are presented as mean ± standard deviation. The χ 2 test was used for sex comparison. The Shapiro-Wilk test was used to confirm the normality of the distribution. For normal distributions, the t test for unpaired data was used to assess the significance of the differences between the means, and the C-reactive protein (hs-CRP) by ELISA (IBL International; www.IBL-International.com), plasma fibroblast growth factor 23 (FGF-23) was determined using a human FGF-23 ELISA kit (Immutopics, www.immutopicsintl.com).
Within 7 days after the end of active treatment, the CACS level was assessed by a multiscan CT and CCA-IMT-by ultrasonography.
Written informed consent was obtained from all subjects before entering the study, and the study protocol was approved by the local ethics committee.
Imaging procedures Multislice CT scanning of the thorax was performed using a General Electric Medical Systems Lightspeed 16 scanner to determine CAC. The acquisition parameters were as follows: 120 KVp, 350 mA, slice with 2.5 mm/8i. Data were reconstructed with a standard algorithm using a 512 × 512 matrix, 50-cm scan field of view, and 25 cm display field of view. The system was synchronized with the cardiac cycle to trigger scanning during the diastolic phase. All pixels with an intensity of 130 Hounsfield units or higher were counted, and the data were analyzed using the CardIQ Smart Score software (GE, Milwaukee, Wisconsin, United States). The CAC score (CACS) was determined using the Agatston scoring system, a CACS threshold of less than 10 AU was considered as indicating no calcification. Forty patients completed the study. The anthropometric and laboratory parameters of the patients from both groups at the beginning and at the end of the treatment are shown in TABLE 1. Two patients were withdrawn during the study: 1 patient from the vitamin K+D group discontinued the treatment owing to bowel discomfort in the fifth week of the study and 1 patient from the D group died in the second month due to myocardial infarction (this patient had diabetes mellitus and a very high CACS, 1902 AU). Two patients from the vitamin K+D group started dialysis therapy during the intervention period (the first one 212 days after the start of the study and the second one after 234 days; their data were included into the final analysis).
The CACS significantly increased in both groups at the end of the treatment period: in the vitamin K+D group from 267.6 ±414.2 to 325.7 ±516.9, P <0.001, and in the vitamin D group from 398.6 ±393.2 to 473 ±507.7, P <0.003 (FIGURE 2). The change of the CACS was slightly lower in the vitamin K+D group than in the vitamin D group (TABLE 2) . While a decrease of the CACS was noticed in 5 patients from the vitamin K+D group (5.4 ±5.2 AU), the CACS did not change in 2 patients. The scope of changes ranged from -11.8 to 380 AU in patients from the vitamin K+D group. In patients treated with vitamin D alone, the CACS increased from 4 to 426.5 AU. When patients with a CACS of 1000 AU or higher were excluded from the analysis, the differences in ΔCACS between patients treated with vitamin K+D and those receiving vitamin D alone showed borderline significance: 18.2 ±29.1 AU vs 39.2 ±49.8, respectively (P = 0.06).
A significantly lower increase of CCA-IMT during the intervention period was noticed in the Bonferroni correction was applied for multiple comparisons. Pearson's linear regression equations were used to determine the power of association between continuous variables, while the Spearman rank correlation coefficient was calculated for variables with nonnormal distribution. Depending on data distribution, the comparison of follow-up data versus baseline was performed using the t test for dependent variables or Wilcoxon test, for independent variables. The Wilcoxon test was used to compare the results before and after the treatment in the same group, and the Mann-Whitney test to compare the results Abbreviations: ANCOVA, analysis of covariance; ΔCACS, change in coronary artery calcification score; ΔCCA-IMT, change in carotid artery intima media thickness patients from the vitamin K+D group (r = 0.65, P = 0.0004, FIGURE 4). Significant correlations between serum phosphorus and ΔCACS (r = 0.47, P = 0.01), similar to the relationship between the calciumphosphate index and ΔCACS (r = 0.47, P = 0.01) were observed only in the vitamin K+D group. No significant correlation between calcification modulators and CACS and CCA-IMT was found. In a stepwise multivariate linear regression analysis performed for patients from both groups together, the CACS, allocation to the treatment group, and age were found to be independent determinants of the ΔCCA-IMT (TABLE 3). The ΔCACS was dependent on the CACS, hs-CRP, 25(OH)D, phosphate, triglyceride, FGF-23, LDL cholesterol, and OC levels (TABLE 4). The allocation to the treatment group had no effect on ΔCACS in this analysis.
DISCUSSION To the best of our knowledge, this study is the first to assess the effect of vitamin K 2 administration on atherosclerosis and calcification progression in CKD patients. It showed that the progression of CCA-IMT is significantly slower in patients treated with both vitamin K 2 and cholecalciferol compared with patients receiving vitamin D alone. Therefore, since all patients received the same dose of vitamin D, but only in one of the arms vitamin K 2 was administered, by comparing the treatment results from both groups, we could assume that the differences between the groups were dependent mainly on the effects of vitamin K 2 . This is consistent with a previous observation of Gast et al 15 that high dietary intake of menaquinones may protect against the development of coronary heart disease. Shanahan et al 16 showed that MGP mRNA was present in the normal media, but its expression was the greatest in the atheromatous intima. The immunohistochemical data reported by Schurgers et al 9 demonstrated that undercarboxylated MGP is abundantly present in atherosclerotic intima and in media sclerosis, suggesting local vitamin K deficiency and impaired protection attributable to poor MGP carboxylation. 9 A tendency to slow the progression of CAC in patients who received both vitamins K 2 and D was observed in the present study, mostly in patients with less advanced baseline calcification. However, the change between both treated groups was relatively small, probably due to a short follow-up period, insufficient number of patients, and a wide range of CACS at baseline. Furthermore, in this study, although regression and stabilization of CACS was noticed in a few patients supplemented with MK-7, such effect was not observed in the vitamin D group. Previously, Shea et al 17 showed that the supplementation of vitamin K 1 for 3 years slowed the progression of VC in elderly people with preexisting calcification. A number of studies concluded that these 2 processes, atherosclerosis and VC, are different pathologies, 18 while others showed that they were closely related and VC represented a more advanced atherosclerotic vitamin K+D group from 0.95 ±0.2 to 1.01 ±0.3, P <0.003 than in the D group: from 1.02 ±0.2 to 1.16 ±0.3, P <0.003 (FIGURE 3, TABLE 2 ). After 9 months of vitamin K 2 supplementation, a significant decrease of dp-ucMGP was observed. This effect was not observed in the vitamin D group. A significant increase of serum OPG levels was found in the vitamin K+D group. A significant increase of serum OC concentrations was observed in patients treated with vitamin D alone, in contrast to the vitamin K+D group, in which the serum concentration of OC decreased. A borderline increase in the FGF-23 level in K+D patients during the treatment was observed, while in the vitamin D group, it did not change. The changes in laboratory parameters between the study groups at the end of the study are presented in TABLE 1.
A strong linear correlation was noted between changes over time of ΔCACS and ΔCCA-IMT in 30 showed a decrease in total and LDL cholesterol levels after 6 months of supplementation with 45 µg of vitamin K in patients on peritoneal dialysis. We did not observe any significant effect of vitamin K 2 substitution on lipid levels, but all our study patients were treated with statins before and during vitamin substitution.
The limitations of our study include a small sample size, resulting in the statistical power that does not allow clinically relevant conclusions to be drawn. A follow-up interval of 270 days may have been too short to detect the differences in the progression of atherosclerosis and VC, which develop over many years. On the other hand, the development of vascular wall changes in CKD patients is faster than in the general population.
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Our study group was quite homogenous, but the treatment groups were different in baseline eGFR, uric acid, phosphate and calcium × phosphate products, and hemoglobin level. The baseline values of CACS and CCA-IMT were not significantly different between the vitamin K+D and vitamin D groups but were slightly lower in the former, hence the effect of the baseline values on our final observation cannot be excluded. The power of the test used to compare the effect of vitamin K+D versus vitamin D alone on the ΔCACS and ΔCCA-IMT was insufficient due to the small group of patients and a wide range of baseline values. Furthermore, only 1 dose of MK-7 was studied and the vitamin K concentration was not process that involved both layers. [19] [20] [21] Our study showed a strong correlation between the changes of CACS and CCA-IMT. Considering the common background of these 2 pathologies, we suspect that supplementing vitamin K 2 for a longer time could result in a more distinct inhibition of calcification process.
Deficiency of carboxylated MGP may contribute substantially to the development and progression of arterial calcification. Areas of calcification in vascular tissue are associated with accumulation of unMGP species, which has also been found to precede the development of clinically overt calcification in children on dialysis. 22 In our study, the serum level of dp-ucMGP decreased significantly during vitamin K 2 supplementation. The substitution of vitamin K 2 could possibly cause an increase in MGP carboxylation in the vascular wall and slow down the progression of atherosclerosis.
Previous studies evaluating the association of OC with VC and cardiovascular disease have provided conflicting results. One study demonstrated that higher OC levels are associated with lower vascular stiffness and CCA-IMT, 23 whereas another showed that higher OC levels are associated with more advanced VC in animal models. 24 
Parker et al
25 observed no association of OC and aortic calcification in postmenopausal women. In our study, the OC level decreased during the substitution of vitamin K 2 with vitamin D. This phenomenon seems to be dependent on vitamin K 2 concentration as the OC level was found to increase in patients from the reference group receiving vitamin D alone.
OPG has been proposed as a protective factor against VC. 26 In our study, the serum OPG increased during supplementation with vitamin K 2 . Our findings confirm the previous experimental 27 and human studies 28 measured before and after the treatment; however, the patient's compliance may be confirmed by the change of dp-ucMGP and 25(OH)D levels observed in both groups. In addition, we did not notice any significant differences between the treated groups over time; we only found differences within the groups and between the groups at baseline and at final measurement. Another limitation of the study is that we did not distinguish between different forms of OC (carboxylated, uncarboxylated), which made the interpretation of the results more difficult.
In conclusion, a 270-day course of vitamin K 2 administration (90 μg) may reduce the progression of atherosclerosis in nondialysis subjects with CKD stages 3-5, but does not have a significant effect on CAC progression. Larger studies are needed to confirm whether vitamin K 2 needs to be supplemented in CKD patients for the prevention of atherosclerosis and VC. The mechanisms by which vitamin K 2 may exert a protective effect on the progression of vessel damage are still uncertain, but may be associated with the effect of MK-7 on the regulators of calcification, including the impact on the MGP carboxylation process.
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